Inhaled nanoparticles target scarring in transplanted lungs
NCT ID NCT07234760
Summary
This research tested a new experimental treatment for chronic lung rejection (BOS) that can occur after a lung transplant. The treatment uses tiny particles (liposomes) designed to carry an existing drug (everolimus) directly into the lungs via an inhaler. The goal is to target the scarring process more effectively while reducing the drug's serious side effects, which often cause patients to stop treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME (BOS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy
Conditions
Explore the condition pages connected to this study.